# OnCo record papillary-rcc (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/papillary-rcc/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "papillary-rcc" ;
  schema:name "Papillary renal cell carcinoma"@en ;
  schema:alternateName "KIRP"@en, "TCGA-KIRP"@en, "kidney renal papillary cell carcinoma (TCGA KIRP cohort)"@en, "pRCC"@en, "Papillary RCC"@en ;
  schema:description "Papillary kidney cancer is the second commonest type and does not share the VHL biology of clear cell cancer, so the drugs work differently: the MET-targeting drug cabozantinib beat sunitinib in the first trial run just for this disease, and two hereditary syndromes account for some cases."@en ;
  schema:url <https://onco.cc/cancers/papillary-rcc/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Papillary_renal_cell_carcinomas> ;
  schema:citation <https://en.wikipedia.org/wiki/Papillary_renal_cell_carcinomas> ;
  onco:tag "subtype-page" ;
  onco:related <https://onco.cc/cancers/chromophobe-rcc/>, <https://onco.cc/cancers/clear-cell-rcc/> ;
  onco:trials <https://onco.cc/trials/papmet/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-who-2022-gu-moch-eur-urol-2022/>, <https://onco.cc/key-papers/paper-aspen-armstrong-lancet-oncol-2016/>, <https://onco.cc/key-papers/paper-papmet-pal-lancet-2021/>, <https://onco.cc/key-papers/paper-tcga-papillary-rcc-nejm-2016/> ;
  onco:pipeline <https://onco.cc/drugs/savolitinib/>, <https://onco.cc/drugs/cabozantinib/> ;
  onco:standardOfCare <https://onco.cc/technologies/thermal-ablation/>, <https://onco.cc/technologies/active-surveillance/>, <https://onco.cc/drugs/cabozantinib/>, <https://onco.cc/drugs/savolitinib/>, <https://onco.cc/targets/met/>, <https://onco.cc/drugs/sunitinib/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/targets/met/> .